Effects of glucagon on resting and exercise haemodynamics in patients with coronary heart disease

Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart

BACKGROUND

Glucagon is thought to increase heart rate and contractility by stimulating glucagon receptors and increasing 3',5'-cyclic adenosine monophosphate (cAMP) production in the myocardium. This has been confirmed in animal studies but not in the human heart. The cardiostimulatory effects of glucagon have been correlated with the degree of cardiac dysfunction, as well as with the enzymatic activity of phosphodiesterase (PDE), which hydrolyses cAMP. In this study, the presence of glucagon receptors in the human heart and the inotropic and chronotropic effects of glucagon in samples of failing and nonfailing (NF) human hearts were investigated.

METHODS

Concentration‒response curves for glucagon in the absence and presence of the PDE inhibitor IBMX were performed on samples obtained from the right (RA) and left atria (LA), the right (RV) and left ventricles (LV), and the sinoatrial nodes (SNs) of failing and NF human hearts. The expression of glucagon receptors was also investigated. Furthermore, the inotropic and chronotropic effects of glucagon were examined in rat hearts.

RESULTS

In tissues obtained from failing and NF human hearts, glucagon did not exert inotropic or chronotropic effects in the absence or presence of IBMX. IBMX (30 µM) induced a marked increase in contractility in NF hearts (RA: 83 ± 28% (n = 5), LA: 80 ± 20% (n = 5), RV: 75 ± 12% (n = 5), and LV: 40 ± 8% (n = 5), weaker inotropic responses in the ventricular myocardium of failing hearts (RV: 25 ± 10% (n = 5) and LV: 10 ± 5% (n = 5) and no inotropic responses in the atrial myocardium of failing hearts. IBMX (30 µM) increased the SN rate in failing and NF human hearts (27.4 ± 3.0 beats min^-1, n = 10). In rat hearts, glucagon induced contractile and chronotropic responses, but only contractility was enhanced by 30 µM IBMX (maximal inotropic effect of glucagon 40 ± 8% vs. 75 ± 10%, in the absence or presence of IBMX, n = 5, P < 0.05; maximal chronotropic response 77.7 ± 6.4 beats min^-1 vs. 73 ± 11 beats min^-1, in the absence or presence of IBMX, n = 5, P > 0.05). Glucagon receptors were not detected in the human heart samples.

CONCLUSIONS

Our results conflict with the view that glucagon induces inotropic and chronotropic effects and that glucagon receptors are expressed in the human heart.

Hemodynamic Effects of Glucagon: A Literature Review

CONTEXT

Glucagon's effects on hemodynamic parameters, most notably heart rate and cardiac contractility, are often overlooked. The glucagon receptor is a central target in novel and anticipated type 2 diabetes therapies, and hemodynamic consequences of glucagon signaling have therefore become increasingly important. In this review, we summarize and evaluate published studies on glucagon pharmacology with a focus on clinical hemodynamic effects in humans.

EVIDENCE ACQUISITION

PubMed, Embase, and the Cochrane Library were searched for clinical studies concerning hemodynamic effects of glucagon (no year restriction). Papers reporting effects of a defined glucagon dose on any hemodynamic parameter were included. Reference searches were conducted in retrieved articles.

EVIDENCE SYNTHESIS

Hemodynamic effects of glucagon have been investigated mainly in cohort studies of patients suffering from heart failure receiving large glucagon bolus injections. The identified studies had shortcomings related to restricted patient groups, lack of a control group, randomization, or blinding. We identified no properly conducted randomized clinical trials. The majority of human studies report stimulating effects of pharmacological glucagon doses on heart rate, cardiac contractility, and blood pressure. The effects were characterized by short duration, interindividual variation, and rapid desensitization. Some studies reported no measurable effects of glucagon.

CONCLUSIONS

The level of evidence regarding hemodynamic effects of glucagon is low, and observations in published studies are inconsistent. Actual effects, interindividual variation, dose-response relationships, and possible long-term effects of supraphysiological glucagon levels warrant further investigation.

The effect of repeated supine exercise on exercise tolerance and left ventricular pump function in patients with angina pectoris

The reproducibility of symptoms, exercise tolerance and haemodynamic variables describing left ventricular pump function have been studied at rest and during repeated supine exercise in ten patients with severe angina pectoris. Two exercise periods were performed about 20 min apart and the breaking point was in all cases determined by angina pectoris. The average working capacity was 22.5 W in both exercise periods. Duration of work, time to onset of angina and pain level at breaking point were not different in the two periods. There were no significant differences at rest nor during exercise for oxygen uptake, arterio-venous oxygen difference, heart rate, cardiac output, stroke volume, left ventricular systolic and end-diastolic pressure, pulmonary artery mean pressure, right atrial mean pressure, stroke work index or left ventricular work. Pressure-time index was significantly (P less than 0.01) higher in the second rest period but systolic pressure heart rate product was not significantly different. The high reproducibility with very small variations of the variables studied should permit the use of this protocol to study the acute haemodynamic effects of pharmacological interventions at rest and during exercise in patients with severe effort-induced angina pectoris.